Accessibility Menu

Regeneron Pharmaceuticals(FRA) RGO

Market Cap€71.07BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPON/A
5 YearN/A
1 YearN/A
1 MonthN/A
€679.50
-1.57%
-10.80Today

Regeneron Pharmaceuticals Financials at a Glance

Market Cap

€71.07BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€13.32K

Net Income (TTM)

€3.71K

EPS (TTM)

€34.70

P/E Ratio

19.89

Dividend

€3.18

Beta (Volatility)

-0.01 (Low)

Price

€679.50

Volume

0

Open

€679.50

Previous Close

€679.50

Daily Range

€679.50 - €679.50

52-Week Range

€471.70 - €719.20

Estimated Earnings Date

N/A

RGO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Industry

Biotechnology

Sector

Health Care

Employees

15,410

CEO

Leonard S. Schleifer, MD, PhD

Website

www.regeneron.com

RGO Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

13.94%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

5.03%

Dividend Yield

0.46%

Payout Ratio

N/A

Stock Overview

Market Cap

€71.07BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

102.95M

Volume

0

Avg. Volume

6.303

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Regeneron Pharmaceuticals Performance Analysis

Regeneron Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 11,582,490,464-14.8%
20232023-12-31EUR 12,133,022,5594.8%
20242024-12-31EUR 13,129,445,6548.2%
20252025-12-31EUR 12,708,825,290-3.2%
Regeneron Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 36.37-40.3%
20232023-12-31EUR 32.16-11.6%
20242024-12-31EUR 35.4410.2%
20252025-12-31EUR 36.763.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€3.69K

+1.1%

Gross Profit

€3.09K

+1.2%

Gross Margin

83.68%

+1.0%

Market Cap

€71.07BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

€3.75

N/A

Employees

15,410

N/A

Net Income

€1.12K

+0.9%

EBITDA

€1.33K

+1.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€4.52K

+12.5%

Total Debt

€2.37K

+1.0%

Accounts Receivable

€5.74K

+1.2%

Inventory

€2.70K

+1.0%

Long Term Debt

€1.74K

+0.8%

Short Term Debt

€629.76

N/A

Return on Assets

10.75%

+0.9%

Return on Invested Capital

19.13%

+0.9%

Free Cash Flow

€497.14

+0.7%

Operating Cash Flow

€704.95

+0.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About RGO

What is the current price of Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals is trading at €679.50 per share.

What is the 52-week range for Regeneron Pharmaceuticals?

Over the past 52 weeks, Regeneron Pharmaceuticals has traded between €471.70 and €719.20.

How much debt does Regeneron Pharmaceuticals have?

As of the most recent reporting period, Regeneron Pharmaceuticals reported total debt of €2.37B.

How much cash does Regeneron Pharmaceuticals have on hand?

Regeneron Pharmaceuticals reported €2.16B in cash and cash equivalents in its most recent financial results.

What is Regeneron Pharmaceuticals’s dividend yield?

Regeneron Pharmaceuticals currently has a dividend yield of 0.46%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services